ChromaDex forms JV to commercialize Tru Niagen in China; gets 71% voting interest

Niagen Bioscience, Inc.

JV partners Crystal Lake, Pioneer Idea, Taikuk contribute $1.8M, $1.2M, $1.0M total $4M into the JV.
ChromaDex holds 71% voting interest, appoints 3 of 5 directors; Taikuk gets 11% non-voting interest after $1M fee.
JV to commercialize Tru Niagen and other NR products in Mainland China (excl. HK, Macau, Taiwan) under 20-year term.
Health food (Blue Hat) registration with China SAMR required for broad distribution; must be obtained within 24 months of closing.
JV expects to enter distribution agreement with Sinopharm Xingsha upon regulatory approval; closing targeted by Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.